

19.04.18

ASX ANNOUNCEMENT

ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

Admedus Limited (ASX:AHZ)

ADMEDUS TAVR GAINING MOMENTUM WITH NEW PATENT APPLICATIONS

Admedus Limited (ASX:AHZ) today announced that it has submitted several new provisional IP applications in the US for further development of its novel Transcatheter Aortic Valve Replacement (TAVR) device.

The provisional patents relate to the engineering of key TAVR device components; two of which are designed to improve 'French size', as well as valve placement and positioning, and a third designed to reduce the incidence of paravalvular leakage (PVL) which can lead to higher morbidity and poor health outcomes for patients.

Admedus' new TAVR device is designed to reduce the risks associated with the insertion and placement of the valve; the specially engineered Everest delivery system offers greater precision deployment and placement mechanisms which allow the surgeon to achieve a more optimal fit and reduce the risk of PVL.

These three components have been designed to complement the Admedus single piece moulded valve, and to address significant unmet need in the areas of access site vascular injury, valve positioning and placement, and PVL.

TAVR is considered the best alternative treatment for patients unable to undergo surgical aortic valve replacement (SAVR) and demand for TAVR devices is growing rapidly - current market value is estimated at US\$3.5B, expected to increase to US\$5B by 2020.

Having previously submitted IP applications for a unique 3D moulded single-piece valve, using our novel ADAPT® tissue technology, and patented sterile hydro-packaging, Admedus is looking to revolutionise the design and engineering of TAVR devices.

Admedus CEO Wayne Paterson welcomed this development,

"This is another significant step forward for Admedus as these patent applications take the Company into new territory. Developing our engineering expertise as we build on the success of our clinically-superior ADAPT® tissue technology."

Admedus Limited
ABN 35 088 221 078

Registered Office
Level 9
301 Coronation Drive
Milton QLD 4064

Customer Service
T 1300 550 310
F 1300 880 398

International
T: +61 8 9266 0100
F: +61 8 9266 0199

E: info@admedus.com
W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore

“These new innovations are above and beyond our tissue science and are based on feedback from the leading physicians who form our permanent TAVR Advisory board. By leveraging their valuable insight and perspective, Admedus is developing breakthrough solutions that are both clinically and commercially relevant.”

“Admedus’ TAVR project is an exciting opportunity to highlight our growing confidence and expertise as a credible and bankable medical technology company with evolving engineering capabilities, beyond our world-leading tissue engineering skills.”

“The benefits of our clinically-superior ADAPT® technology and tissue products are now scientifically proven beyond doubt with a decade of clinical data to demonstrate its superior resistance to calcification and toxicity.”

“Combining innovative engineering with cutting-edge science, Admedus aims to create the best TAVR device on the market – less expensive to produce, more efficient to use, and most importantly, delivering optimal health outcomes for patients,” he said.

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus

Twitter: @Admedus

For more information, please contact:

Admedus Limited

Barbara Ferres

+61 7 3152 3216

communications@admedus.com

Admedus Limited
ABN 35 088 221 078

Registered Office
Level 9
301 Coronation Drive
Milton QLD 4064

Customer Service
T 1300 550 310
F 1300 880 398

International
T: +61 8 9266 0100
F: +61 8 9266 0199

E: info@admedus.com
W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore